Cary, N.C. , Sept. 25, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Crinetics Pharmaceuticals as a limited specialty pharmacy provider for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist for the treatment of acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option.
Acromegaly develops when a benign pituitary tumor develops and secretes increased levels of growth hormone (GH). Acromegaly is characterized by somatic overgrowth (often in the hands, feet and face), and other physical changes, joint pain, metabolic disorders, cardiovascular disease and respiratory problems, among others. When left untreated, acromegaly can lead to premature mortality.
“As the first-and-only once-daily, oral therapy for acromegaly, Palsonify represents a significant advancement for patients managing this rare and serious condition,” says George Paschal, senior director, business development, Biologics by McKesson. “Biologics by McKesson is proud to have been selected by Crinetics Pharmaceuticals as a specialty pharmacy provider for Palsonify. This partnership reflects our continued commitment to supporting access to innovative treatments for patients with rare diseases, and to partnering with biopharma manufacturers at the leading edge of scientific advancement.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information for Palsonify, please click here. For more information about the treatment of patients with acromegaly, please visit PALSONIFY.com.